Cargando…
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage resp...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866212/ https://www.ncbi.nlm.nih.gov/pubmed/34716195 http://dx.doi.org/10.1158/1078-0432.CCR-21-2863 |
_version_ | 1784655787276107776 |
---|---|
author | Venugopal, Kartika Feng, Yang Nowialis, Pawel Xu, Huanzhou Shabashvili, Daniil E. Berntsen, Cassandra M. Kaur, Prabhjot Krajcik, Kathryn I. Taragjini, Christina Zaroogian, Zachary Casellas Román, Heidi L. Posada, Luisa M. Gunaratne, Chamara Li, Jianping Dupéré-Richer, Daphné Bennett, Richard L. Pondugula, Santhi Riva, Alberto Cogle, Christopher R. Opavsky, Rene Law, Brian K. Bhaduri-McIntosh, Sumita Kubicek, Stefan Staber, Philipp B. Licht, Jonathan D. Bird, Jonathan E. Guryanova, Olga A. |
author_facet | Venugopal, Kartika Feng, Yang Nowialis, Pawel Xu, Huanzhou Shabashvili, Daniil E. Berntsen, Cassandra M. Kaur, Prabhjot Krajcik, Kathryn I. Taragjini, Christina Zaroogian, Zachary Casellas Román, Heidi L. Posada, Luisa M. Gunaratne, Chamara Li, Jianping Dupéré-Richer, Daphné Bennett, Richard L. Pondugula, Santhi Riva, Alberto Cogle, Christopher R. Opavsky, Rene Law, Brian K. Bhaduri-McIntosh, Sumita Kubicek, Stefan Staber, Philipp B. Licht, Jonathan D. Bird, Jonathan E. Guryanova, Olga A. |
author_sort | Venugopal, Kartika |
collection | PubMed |
description | PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage response and replication fork integrity, suggesting sensitivity to replication stress. Here, we tested whether pharmacologically induced replication fork stalling, such as with cytarabine, creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations. EXPERIMENTAL DESIGN: Leukemia cell lines, genetic mouse models, and isogenic cells with and without DNMT3A(mut) were used to evaluate sensitivity to nucleoside analogues such as cytarabine in vitro and in vivo, followed by analysis of DNA damage and signaling, replication restart, and cell-cycle progression on treatment and after drug removal. Transcriptome profiling identified pathways deregulated by DNMT3A(mut) expression. RESULTS: We found increased sensitivity to pharmacologically induced replication stress in cells expressing DNMT3A(R882)-mutant, with persistent intra–S-phase checkpoint activation, impaired PARP1 recruitment, and elevated DNA damage, which was incompletely resolved after drug removal and carried through mitosis. Pulse-chase double-labeling experiments with EdU and BrdU after cytarabine washout demonstrated a higher rate of fork collapse in DNMT3A(mut)-expressing cells. RNA-seq studies supported deregulated cell-cycle progression and p53 activation, along with splicing, ribosome biogenesis, and metabolism. CONCLUSIONS: Together, our studies show that DNMT3A mutations underlie a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which may have therapeutic tractability. These results demonstrate that, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during replication stress. See related commentary by Viny, p. 573 |
format | Online Article Text |
id | pubmed-8866212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-88662122022-02-24 DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks Venugopal, Kartika Feng, Yang Nowialis, Pawel Xu, Huanzhou Shabashvili, Daniil E. Berntsen, Cassandra M. Kaur, Prabhjot Krajcik, Kathryn I. Taragjini, Christina Zaroogian, Zachary Casellas Román, Heidi L. Posada, Luisa M. Gunaratne, Chamara Li, Jianping Dupéré-Richer, Daphné Bennett, Richard L. Pondugula, Santhi Riva, Alberto Cogle, Christopher R. Opavsky, Rene Law, Brian K. Bhaduri-McIntosh, Sumita Kubicek, Stefan Staber, Philipp B. Licht, Jonathan D. Bird, Jonathan E. Guryanova, Olga A. Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage response and replication fork integrity, suggesting sensitivity to replication stress. Here, we tested whether pharmacologically induced replication fork stalling, such as with cytarabine, creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations. EXPERIMENTAL DESIGN: Leukemia cell lines, genetic mouse models, and isogenic cells with and without DNMT3A(mut) were used to evaluate sensitivity to nucleoside analogues such as cytarabine in vitro and in vivo, followed by analysis of DNA damage and signaling, replication restart, and cell-cycle progression on treatment and after drug removal. Transcriptome profiling identified pathways deregulated by DNMT3A(mut) expression. RESULTS: We found increased sensitivity to pharmacologically induced replication stress in cells expressing DNMT3A(R882)-mutant, with persistent intra–S-phase checkpoint activation, impaired PARP1 recruitment, and elevated DNA damage, which was incompletely resolved after drug removal and carried through mitosis. Pulse-chase double-labeling experiments with EdU and BrdU after cytarabine washout demonstrated a higher rate of fork collapse in DNMT3A(mut)-expressing cells. RNA-seq studies supported deregulated cell-cycle progression and p53 activation, along with splicing, ribosome biogenesis, and metabolism. CONCLUSIONS: Together, our studies show that DNMT3A mutations underlie a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which may have therapeutic tractability. These results demonstrate that, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during replication stress. See related commentary by Viny, p. 573 American Association for Cancer Research 2022-02-15 2021-10-28 /pmc/articles/PMC8866212/ /pubmed/34716195 http://dx.doi.org/10.1158/1078-0432.CCR-21-2863 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Translational Cancer Mechanisms and Therapy Venugopal, Kartika Feng, Yang Nowialis, Pawel Xu, Huanzhou Shabashvili, Daniil E. Berntsen, Cassandra M. Kaur, Prabhjot Krajcik, Kathryn I. Taragjini, Christina Zaroogian, Zachary Casellas Román, Heidi L. Posada, Luisa M. Gunaratne, Chamara Li, Jianping Dupéré-Richer, Daphné Bennett, Richard L. Pondugula, Santhi Riva, Alberto Cogle, Christopher R. Opavsky, Rene Law, Brian K. Bhaduri-McIntosh, Sumita Kubicek, Stefan Staber, Philipp B. Licht, Jonathan D. Bird, Jonathan E. Guryanova, Olga A. DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title | DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title_full | DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title_fullStr | DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title_full_unstemmed | DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title_short | DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks |
title_sort | dnmt3a harboring leukemia-associated mutations directs sensitivity to dna damage at replication forks |
topic | Translational Cancer Mechanisms and Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866212/ https://www.ncbi.nlm.nih.gov/pubmed/34716195 http://dx.doi.org/10.1158/1078-0432.CCR-21-2863 |
work_keys_str_mv | AT venugopalkartika dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT fengyang dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT nowialispawel dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT xuhuanzhou dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT shabashvilidaniile dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT berntsencassandram dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT kaurprabhjot dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT krajcikkathryni dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT taragjinichristina dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT zaroogianzachary dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT casellasromanheidil dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT posadaluisam dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT gunaratnechamara dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT lijianping dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT duperericherdaphne dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT bennettrichardl dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT pondugulasanthi dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT rivaalberto dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT coglechristopherr dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT opavskyrene dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT lawbriank dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT bhadurimcintoshsumita dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT kubicekstefan dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT staberphilippb dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT lichtjonathand dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT birdjonathane dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks AT guryanovaolgaa dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks |